The compound, named it, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans. it is an orally bioavailable, peptidomimetic, macrocyclic compound with activity against hepatitis C virus (HCV). it binds non-covalently to the active center of the HCV NS3-4A serine protease and prevents processing of viral proteins required for replication. 
